Batchelor, W., Mahaffey, K., Berger, P., Deutsch, E., Meier, S., Hasselblad, V., … Berger, P. B. (2002). Enoxaparin may reduce the risk of myocardial infarction among people at increased risk of stent thrombosis, but is unnecessary for most people. Evidence-Based Cardiovascular Medicine, 6(4), 137–138. https://doi.org/10.1054/ebcm.2002.0488

Batchelor, W., K. Mahaffey, P. Berger, E. Deutsch, S. Meier, V. Hasselblad, E. Fry, et al. “Enoxaparin may reduce the risk of myocardial infarction among people at increased risk of stent thrombosis, but is unnecessary for most people.” Evidence-Based Cardiovascular Medicine 6, no. 4 (January 1, 2002): 137–38. https://doi.org/10.1054/ebcm.2002.0488.

Batchelor W, Mahaffey K, Berger P, Deutsch E, Meier S, Hasselblad V, et al. Enoxaparin may reduce the risk of myocardial infarction among people at increased risk of stent thrombosis, but is unnecessary for most people. Evidence-based Cardiovascular Medicine. 2002 Jan 1;6(4):137–8.

Batchelor, W., et al. “Enoxaparin may reduce the risk of myocardial infarction among people at increased risk of stent thrombosis, but is unnecessary for most people.” Evidence-Based Cardiovascular Medicine, vol. 6, no. 4, Jan. 2002, pp. 137–38. Scopus, doi:10.1054/ebcm.2002.0488.

Batchelor W, Mahaffey K, Berger P, Deutsch E, Meier S, Hasselblad V, Fry E, Teirstein P, Ross A, Binanay C, Zidar J, Berger PB. Enoxaparin may reduce the risk of myocardial infarction among people at increased risk of stent thrombosis, but is unnecessary for most people. Evidence-based Cardiovascular Medicine. 2002 Jan 1;6(4):137–138.